All Stories

  1. Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A
  2. Recombinant protein materials for bioengineering and nanomedicine
  3. General Introduction: Recombinant Protein Production and Purification of Insoluble Proteins
  4. In Vivo Architectonic Stability of Fully de Novo Designed Protein-Only Nanoparticles
  5. Biomedical Applications of Bacterial Inclusion Bodies
  6. Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery
  7. Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy
  8. A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs
  9. Multifunctional Nanovesicle-Bioactive Conjugates Prepared by a One-Step Scalable Method Using CO 2 -Expanded Solvents
  10. Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies
  11. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics
  12. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles
  13. Enzymatic characterization of highly stable human alpha-galactosidase A displayed on magnetic particles
  14. Nanopills: Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies (Adv. Mater. 13/2012)
  15. Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies
  16. Bacterial inclusion bodies: making gold from waste
  17. Packaging protein drugs as bacterial inclusion bodies for therapeutic applications
  18. Integrated approach to produce a recombinant, his-tagged human α-galactosidase a in mammalian cells
  19. Self-assembling, protein-based intracellular bacterial organelles: emerging vehicles for encapsulating, targeting and delivering therapeutical cargoes
  20. Post-production protein stability: trouble beyond the cell factory
  21. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine
  22. Properties of Human Alpha-galactosidase A Immobilized on Different-sized Magnetic Particles through Different Methods
  23. Integrated Approach to Optimize Transient Gene Expression in Mammalian Cells: Production of a Recombinant Human Alpha-galactosidase A
  24. Recombinant production of a difficult-to-express eukaryotic protein in a bacterial expression system
  25. Bacterial inclusion bodies as novel functional and biocompatible nanomaterials
  26. Biomedical applications of distally controlled magnetic nanoparticles
  27. Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial
  28. Modular Protein Engineering in Emerging Cancer Therapies
  29. Microbial factories for recombinant pharmaceuticals
  30. Control of Escherichia coli growth rate through cell density
  31. Comparison of Serologic Assays for Detection of Antibodies against Human Herpesvirus 8
  32. Cell lysis in Escherichia coli cultures stimulates growth and biosynthesis of recombinant proteins in surviving cells
  33. Tolerance ofEscherichia coli ?-galactosidase C-terminus to different-sized fusions
  34. Proteolytic digestion of bacterial inclusion body proteins during dynamic transition between soluble and insoluble forms
  35. Heat-inactivation of plasmid-encoded CI857 repressor induces gene expression from Ind − lambda prophage in recombinant Escherichia coli
  36. The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response inEscherichia coli
  37. The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in Escherichia coli
  38. The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response inEscherichia coli
  39. Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria
  40. Plasmid maintenance in Escherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins
  41. Plasmid maintenance inEscherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins
  42. Reversible activation of a cryptic cleavage site within E. coli β-galactosidase in β-galactosidase fusion proteins
  43. Antigenicity of a viral peptide displayed on β-galactosidase fusion proteins is influenced by the presence of the homologous partner protein
  44. Antigenicity of a viral peptide displayed on β-galactosidase fusion proteins is influenced by the presence of the homologous partner protein
  45. The position of the heterologous domain can influence the solubility and proteolysis of β-galactosidase fusion proteins in E. coli
  46. A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response in
  47. A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response in Escherichia coli
  48. Mitomycin C stimulates thermally induced recombinant gene expression in Escherichia coli MC strains
  49. Ammonium-Mediated Reduction of Plasmid Copy Number and Recombinant Gene Expression in Escherichia coli
  50. Production of thermally induced recombinant proteins relative to cell biomass is influenced by cell density in Escherichia coli batch cultures